SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA Pharmaceuticals
Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing
innovative technology to fuel drug discovery and clinical
development of novel treatments for central nervous system
disorders, today announced that the company will present at the
2007 International Congress on Schizophrenia Research, held from
March 28 through April 1, 2007, in Colorado Springs, Colorado.
Presentations will cover ACADIA's two schizophrenia programs and
will include previously announced top-line clinical data from the
recently completed ACP-103 Phase II schizophrenia co-therapy trial,
as well as preclinical and top-line clinical data on ACP-104 for
the treatment of schizophrenia.

ACP-103: Top-Line Data from Phase II Schizophrenia Co-Therapy
Trial

Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA, will
make an oral presentation on April 1 titled "ACP-103, a 5-HT2A
Inverse Agonist in Schizophrenia and Parkinson's Disease
Psychosis." This presentation will include previously announced
top-line results from the recently completed ACP-103 Phase II
schizophrenia co-therapy trial, which highlighted several
advantages of co-therapy with ACP-103, including enhanced efficacy,
a faster onset of antipsychotic action, and an improved side effect
profile. Dr. Hacksell also will present new data from this study
showing that patients in the co-therapy arm combining ACP-103 with
risperidone (2 mg) had significantly lower prolactin levels after
42 days of treatment compared to patients in the risperidone (6 mg)
plus placebo arm (p=0.0001). The condition of elevated prolactin is
a commonly observed side effect of antipsychotic therapy and may
adversely affect menstrual and sexual function as well as bone
formation.

ACP-104: Top-Line Data From Single Ascending-Dose and Multiple
Ascending-Dose Studies

Professor Carol Tamminga, M.D., from the University of Texas
Sout
hwestern Medical School, will make on oral presentation on
April 1 titled "ACP-104 Novel Atypical Antipsychotic with Potential
Cognitive Effects." During the presentation, Dr. Tamminga will
review the unique preclinical properties of ACP-104 as well as
top-line clinical results from the single ascending-dose and
multiple ascending-dose studies with ACP-104, which were announced
in July 2006. Additionally, data from the single ascending-dose
study will be presented in a poster titled "ACP-104 Safety and
Pharmacokinetics in Psychosis."

ACP-104: Demonstrates Pro-Cognitive Actions in Experimental
Models

In a poster presentation titled "N-Desmethylclozapine
Demonstrates Pro-Cognitive Actions in Experimental Models," ACADIA
researchers describe preclinical data that indicate ACP-104, in
addition to being active in models predictive of antipsychotic
activity, has a superior profile in animal models of cognitive
function. ACP-104 showed an improved performance in the Radial Arm
Maze and no adverse effect in the Novel Object Recognition assay.
In contrast, clozapine impaired performance in both these assays.
The pro-cognitive effects of ACP-104 were shown to be dependent
upon M1 muscarinic activity. These findings suggest that ACP-104
will have a superior clinical profile with activity against all
symptom domains (positive, negative, and cognitive) in
schizophrenia.

ACP-104: Unique Receptor Profile for Treating Psychosis

In a poster presentation titled "Comparison of the In Vitro
Pharmacology of N-Desmethylclozapine (ACP-104) with other Atypical
Antipsychotic Agents," ACADIA researchers describe experiments that
used cell based assays to characterize the functional interaction
of ACP-104 and other antipsychotic drugs with a number of receptors
implicated in the efficacy or adverse effects of antipsychotic
drugs. The results demonstrated that ACP-104 has a receptor profile
that is distinct from and potentially advantageous to clozapine and
other at
ypical antipsychotic agents.

About ACP-103

ACP-103 is a small molecule drug candidate that ACADIA
discovered and is developing as a co-therapy for schizophrenia.
ACP-103 can be taken orally and is a novel, potent, and selective
5-HT2A inverse agonist, meaning that it blocks the activity of the
5-HT2A receptor. By adding ACP-103 to existing schizophrenia
treatment regimens, ACADIA believes the optimal combination of
5-HT2A inverse agonism and dopamine receptor blockade can be
achieved, thereby resulting in enhanced efficacy and fewer side
effects relative to existing treatments. ACADIA also is entering
Phase III development with ACP-103 for the treatment of Parkinson's
disease psychosis. In addition, ACADIA is developing ACP-103 for
the treatment of sleep maintenance insomnia.

About ACP-104

ACP-104, or N-desmethylclozapine, is the major metabolite of
clozapine, and is in Phase II-stage development by ACADIA as a
novel stand-alone therapy for schizophrenia. ACP-104 offers an
atypical antipsychotic efficacy profile with the added potential
benefit of enhanced cognition. ACP-104 combines M1 muscarinic
agonism, 5-HT2A inverse agonism, and D2 and D3 dopamine partial
agonism in a single compound and, therefore, uniquely addresses
what ACADIA believes are the three most promising target mechanisms
for treating schizophrenia. ACADIA's development program for
ACP-104 is supported in part by the Stanley Medical Research
Center.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative
technology to fuel drug discovery and clinical development of novel
treatments for central nervous system disorders. ACADIA currently
has five clinical programs, as well as a portfolio of preclinical
and discovery assets, directed at large unmet medical needs,
including schizophrenia, Parkinson's disease psychosis, sleep
maintenance insomnia, and neuropathic pain. All of the drug
candidates in ACADIA's product pipeline emanat
e from discoveries
made using its proprietary drug discovery platform. ACADIA's
corporate headquarters is located in San Diego, California and it
maintains research and development operations in both San Diego and
Malmo, Sweden.

Forward-Looking Statements

Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to
benefits to be derived from ACADIA's drug development programs,
including the potential advantages of the use of ACP-103 as a
co-therapy for schizophrenia and the use of ACP-104 as a treatment
for schizophrenia. These statements are only predictions based on
current information and expectations and involve a number of risks
and uncertainties. Actual events or results may differ materially
from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in clinical
trials, and drug development and commercialization, including the
uncertainty of whether results in testing of ACP-103 and ACP-104 to
date will be predictive of results in later stages of development.
For a discussion of these and other factors, please refer to
ACADIA's annual report on Form 10-K for the year ended December 31,
2006 as well as other subsequent filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise
or update this press release to reflect events or circumstances
after the date hereof.

(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...

(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...

(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...

(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...

(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...